Global Psoriatic Arthritis Market 2023

September 2023 | 91 pages | ID: G8D8ACA3F330EN
Gen Consulting Company

Abstracts

The global market for psoriatic arthritis treatment is projected to reach USD 12.72 billion by 2029, growing at a CAGR of 6.1% from USD 8.27 billion in 2022. Psoriatic arthritis is a chronic inflammatory rheumatic disease that affects up to 30% of psoriasis patients aged 30 to 60. It is more common in women. The exact cause is unknown, but family history and certain risk factors play a role. Diagnosis involves imaging techniques and symptom evaluation. Treatment options include non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, biologics, and emerging therapies. The market is driven by the introduction of new drugs and the demand for improved treatments. IL inhibitors and oral JAK inhibitors show promise. The market has over 25 assets in development, with many in Phase III trials. The introduction of novel therapies will fuel market growth. Targeting inflammatory pathways beyond TNF, such as IL-23/IL-17, has proven effective. Technological advancements are expected to enhance interventions and outcomes in the future.

The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global psoriatic arthritis market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Market Segmentation
The market is segmented based on various factors, including drug class, disease type, gender type, age group, severity type, and geography.
Drug class: interleukin inhibitors, NSAIDs, TNF inhibitors, others
Disease type: spondylitis, dactylitis, enthesitis
Gender: men, women
Age group: 50 years and below, 50 years and above
Severity type: moderate, mild, severe

Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC - China, Japan

TNF-Alpha inhibitors dominate the global psoriatic arthritis treatment market but the fastest growth is expected in interleukin inhibitors. Approvals of drugs like Skyrizi and Cosentyx will drive the market. Women make up a significant portion of the market due to increased risk. Enthesitis holds a significant share but Dactylitis will grow the fastest. Individuals below 50 will make up a substantial portion. Mild form is significant but moderate form will grow the fastest. The United States dominates the market due to affordability, knowledge, and technology. Germany will experience rapid growth due to healthcare access and awareness. Biosimilars in China and Japan will bring changes. China has the highest number of cases, followed by Spain and the U.K. PsA prevalence is increasing in the European Union.

Competitive Landscape
Major players in the global psoriatic arthritis treatment market include AbbVie Inc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Biogen Inc, UCB SA, Amgen Inc., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, and Novartis AG. These companies are employing strategies such as collaborations, acquisitions, geographic expansion, research and development, and manufacturing novel drugs to strengthen their product portfolios and compete in the market. Other notable players include Bausch Health Companies Inc., Biocad Biopharmaceutical Co., Bio-Thera Solutions, Ltd., Eli Lilly and Company, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Meiji Holdings Co., Ltd., Sun Pharmaceuticals Industries Limited, among others. These players prioritize research and development to develop advanced psoriatic drugs and maintain their industry position.

Scope of the Report
To analyze and forecast the market size of the global psoriatic arthritis market.
To classify and forecast the global psoriatic arthritis market based on drug class, disease type, gender, age group, severity type, geography.
To identify drivers and challenges for the global psoriatic arthritis market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global psoriatic arthritis market.
To identify and analyze the profile of leading players operating in the global psoriatic arthritis market.

Why Choose This Report
Gain a reliable outlook of the global psoriatic arthritis market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience

PART 2. RESEARCH METHODOLOGY

2.1 Primary Research
2.2 Secondary Research

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

4.1 Introduction
4.2 Drivers
4.3 Restraints

PART 5. GLOBAL PSORIATIC ARTHRITIS MARKET BY DRUG CLASS

5.1 Interleukin inhibitors
5.2 NSAIDs
5.3 TNF inhibitors
5.4 Others

PART 6. GLOBAL PSORIATIC ARTHRITIS MARKET BY DISEASE TYPE

6.1 Spondylitis
6.2 Dactylitis
6.3 Enthesitis

PART 7. GLOBAL PSORIATIC ARTHRITIS MARKET BY GENDER

7.1 Men
7.2 Women

PART 8. GLOBAL PSORIATIC ARTHRITIS MARKET BY AGE GROUP

8.1 50 years and below
8.2 50 years and above

PART 9. GLOBAL PSORIATIC ARTHRITIS MARKET BY SEVERITY TYPE

9.1 Moderate
9.2 Mild
9.3 Severe

PART 10. GLOBAL PSORIATIC ARTHRITIS MARKET BY GEOGRAPHY

10.1 North America
10.2 Europe
10.3 APAC

PART 11. COMPANY PROFILES

11.1 AbbVie Inc
11.2 Amgen Inc.
11.3 Bausch Health Companies Inc.
11.4 Biocad Biopharmaceutical Co.
11.5 Biogen Inc
11.6 Bio-Thera Solutions, Ltd.
11.7 Bristol-Myers Squibb Company
11.8 Eli Lilly and Company
11.9 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
11.10 Johnson & Johnson
11.11 Meiji Holdings Co., Ltd.
11.12 Novartis AG
11.13 Pfizer Inc.
11.14 Sun Pharmaceuticals Industries Limited
11.15 Takeda Pharmaceutical Company Limited
11.16 UCB SA
DISCLAIMER